Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis
Sign Up to like & getrecommendations! Published in 2023 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofad159
Abstract: Abstract Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. This mAb binds to complement protein 5… read more here.
Keywords: cryptococcosis following; following eculizumab; eculizumab therapy; pathogenesis ... See more keywords